RA Capital Management is a Boston-based investment firm specializing in healthcare, life sciences, and planetary health. It pursues evidence-based, science-led investing through its internal TechAtlas research engine and supports portfolio companies via its Raven healthcare incubator. The firm engages across stages from seed funding to IPOs and follow-on financings, focusing on drugs, medical devices, diagnostics, and other biomedical innovations, with a regional emphasis on the United States and Europe.

OrbiMed is a global healthcare investment firm based in New York, founded in 1989. It manages capital across public and private markets, including private equity, venture and growth investments, and private credit, with structured debt and royalty arrangements to support owners of intellectual property and diagnostics. The firm focuses on biopharmaceuticals, life sciences, medical devices, diagnostics, health IT, and healthcare services, investing from startups to multinational companies. With a worldwide team and offices in multiple regions, OrbiMed provides financing and strategic resources to advance therapies and healthcare innovations, aiming to improve patient outcomes across global markets.

The Invus Group is a long-standing private equity firm founded in 1985 and based in New York. It partners with entrepreneurs to drive transformative growth across sectors including consumer products and services, technology, life sciences, software, and industrials. The firm emphasizes long-term collaboration, aligns incentives with management, and provides both capital and strategic advisory to help portfolio companies scale internationally. It maintains a global presence with offices in the United States, Europe, and Asia, and pursues flexible investment approaches through evergreen capital structures and co-investment opportunities. The group supports management-led buyouts, growth equity, and select opportunistic investments, aiming to create lasting value rather than short-term gains.

Vivo Capital is a healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Beijing, Shanghai, Hong Kong, and Taipei. It invests in healthcare and life sciences companies across the United States, China, and other global markets, including biotechnology, pharmaceuticals, medical devices, and healthcare services. Its investment activities span venture capital, growth equity, private equity, and public equity.

TCG Crossover is a healthcare investment firm focused on companies developing innovative medicines and treatments. It invests in private and public companies and has teams in Palo Alto, California, and New York City. The firm is based in Palo Alto and invests in companies in the United States and Europe.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, founded in 2016. The firm focuses on the healthcare sector, investing in biotechnology companies across the United States and serving as an investment adviser to support the development of transformative therapeutics. By combining scientists, clinicians, drug developers, and business leaders with extensive experience, Samsara BioCapital aims to accelerate the next generation of therapies through collaborative partnerships and strategic capital. The firm operates as a principal investor and provides guidance to entrepreneurs seeking to turn their ideas into successful biotech ventures.

Forbion is a venture capital firm investing in biotechnology and life sciences, with a focus on human health, planetary health, and the bioeconomy. It backs companies from early stages through clinical development, including businesses developing medicines and sustainable solutions. Headquartered in Naarden, the Netherlands, Forbion operates across Europe and the United States, with offices in the Netherlands, Germany, and the US.

Deep Track Capital is a venture capital firm headquartered in Greenwich, Connecticut. Founded in 2020, it concentrates on the life sciences and biotechnology sectors, investing in public and pre-IPO biotechnology companies. The firm emphasizes a hands-on partnership approach, providing capital, scientific expertise, and an extensive network to management teams. It seeks to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, aiming to accelerate the development and commercialization of innovative biotech ventures.

ARCH Venture Partners is a venture capital firm founded in 1986 and based in Chicago, Illinois, with additional operations in Seattle. The firm focuses on science-based companies, prioritizing life sciences and related technologies, and aims to translate academic and national lab innovations into commercially viable products. ARCH emphasizes a true partnership approach, providing capital alongside strategic guidance, expertise, and a broad professional network to founders. It has supported numerous companies across early to growth stages and is known for backing translational efforts that bring breakthrough discoveries to market, leveraging collaborations with researchers and entrepreneurs to accelerate development of disruptive technologies on a national and international scale.

The European Innovation Council is a European Union institution that funds and accelerates deep-tech innovation across Europe. It provides substantial support to startups, researchers, and technology transfer activities through programs such as the EIC Accelerator, EIC Fund, and EIC Prizes, and offers business acceleration services to help scale and globally expand ventures. The council is described as a major investor, providing about €6.5 billion in funding, and it co-invests with private investors in early-stage startups with ESG impacts. Established in 2018 and headquartered in Brussels, it focuses on breakthrough innovations in deep technology, including dual-use and defence-relevant technologies, and engages with innovation ecosystems through events, reports, and information hubs. The organization is oriented toward advancing European competitiveness by nurturing high-potential tech ventures from inception through scaleup.

Morningside Group is a venture capital firm based in Newton, Massachusetts, founded in 1986 as a family office for the Chan family. It pursues long-term investments in companies with novel science and technology, with active interest in life sciences, digital health, artificial intelligence, materials, and technology sectors. The firm emphasizes ethical business practices and seeks to support the growth of enduring companies. Beyond its investing activities, Morningside supports education, research, and healthcare through charitable commitments to institutions such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

New Enterprise Associates is a venture capital firm headquartered in Menlo Park, California. Founded in 1977, it invests in technology and healthcare companies from seed stage through later growth and public offerings, and provides founders with operational and strategic support. Its investments span areas including software, consumer technology, life sciences, biotechnology, medical devices, and energy technology. The firm operates across the United States, Asia, and Brazil, with offices in the United States, India, and China.

Logos Capital is a biotechnology investment firm based in San Francisco, founded in 2019. It uses a disciplined, data-driven approach that combines in-house analytics with scientific and clinical expertise to identify transformative therapeutics. The firm conducts rigorous fundamental research across clinical, regulatory, operational, and commercial dimensions of drug development, leveraging a proprietary data science platform called Logos Analytics to assess clinical success probability. With an emphasis on risk management, Logos Capital aims to deliver long-term, uncorrelated returns through thorough due diligence and a holistic view of asset value.

Sofinnova Partners is a Paris-based independent venture capital firm focused on life sciences, investing from seed to later-stage in biopharmaceuticals, biotech, medical devices and related industrial biotech opportunities; it partners with entrepreneurs to develop transformative innovations, often taking a lead or cornerstone role, serving on portfolio company boards and guiding them from formation through exit. Founded in 1972, the firm emphasizes long-term partnerships and aims to advance scientific progress in healthcare and sustainability.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on investing in life sciences and related technologies. The firm targets opportunities in healthcare and biotech, including digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity across North America and Western Europe. Omega Funds acts as a registered investment adviser, supporting early-stage and growth companies as they develop therapeutic and digital health solutions.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage biotechnology and life sciences companies. Founded in 1980, it focuses on translating breakthrough science into medicines and medical technologies, often employing a seed-led venture creation approach and taking lead investor roles with board representation. The firm operates with dedicated Life Sciences and Technology teams and invests across the United States and Europe, supporting startups through initial funding and early growth. Its portfolio emphasizes biopharmaceuticals, diagnostics, medical devices, and related platforms, reflecting a commitment to advancing innovative healthcare solutions.

SR One is the corporate venture capital arm of GlaxoSmithKline. It invests globally in life science companies pursuing innovative science with the potential to significantly improve medical care. Based in Redwood City, California, with a London office, SR One follows a back-and-build approach, partnering with founders to translate science into medicines. The firm evaluates opportunities across biotechnology, healthcare, medical devices, and related technology, focusing on companies with strong fundamentals and clear development plans. Its transatlantic presence provides access to high-quality science, strategic collaboration, and geographic reach to support portfolio companies as they advance therapies. SR One aims to accelerate the translation of scientific discovery into transformative treatments by acting as a strategic partner rather than a traditional investor.

Commodore Capital is a New York-based venture capital firm focused on biopharmaceuticals. Founded in 2019, the firm concentrates on early-stage companies developing innovative therapies, with emphasis on genetic medicines and cellular therapies, during a period of rapid scientific advancement translating into clinical breakthroughs. It aims to be a supportive partner to smaller biopharmaceutical companies as they develop and deliver new medicines to patients globally.

EcoR1 Capital is a venture capital firm based in San Francisco that invests in early-stage biotechnology companies developing innovative therapeutics. It applies a scientific approach, leveraging advances in molecular biology to identify promising ventures and support their pursuit of new medicines. The firm emphasizes partnering with entrepreneurs dedicated to therapeutic innovation and provides strategic and scientific guidance to help translate breakthrough discoveries into treatments for patients.

HBM Healthcare Investments is a Swiss investment company focused on healthcare, managing a globally diversified portfolio of private and public healthcare companies. Based in Switzerland and established in 2001, the company targets opportunities across human medicine, biotechnology, diagnostics, and medical technology, seeking to benefit from demographic growth, medical advances, rising prosperity, and the increasing need for new therapies. The business emphasizes exposure to the rapidly expanding global healthcare market through a mix of private holdings, public investments, and related assets, aiming to generate value and long-term growth for investors.

SOSV is a global venture capital firm focused on early-stage deep-tech and cross-border software companies, investing primarily from pre-seed through growth stages. It accelerates product development, regulatory progress, fundraising, and commercial strategy by providing founders access to purpose-built labs, engineering spaces, and a broad physical and virtual infrastructure across multiple locations. The firm's program-driven approach combines selective funding with hands-on support, mentorship, and a wide network of co-investors and partners to help portfolio companies scale. SOSV operates a suite of specialized facilities for deep-tech founders, including incubation programs that connect startups with customers, researchers, and investors, and it emphasizes long-term relationships through ongoing operational and strategic assistance. While active globally, it maintains strong ties to Asia-focused cross-border markets and supports a diverse portfolio spanning bio-tech, hardware, robotics, software, and related fields.

Boxer Capital is a biotech investment firm and the corporate venture capital arm of Tavistock Group, based in San Diego, California. The firm invests in biotechnology and precision medicine companies across private and public markets, spanning the drug development lifecycle from early discovery to late-stage development and commercialization, with a focus on oncology and novel targets. It emphasizes scientific expertise and a disciplined, research-driven due diligence process that includes clinical, regulatory, and commercial assessment. Boxer Capital maintains independent investment decisions and has partnered with portfolio companies such as Mirati Therapeutics to support growth. The firm seeks opportunities in specialized medicine, precision oncology, and related life sciences sectors.

venBio Partners is a California-based venture capital firm focused on life sciences, investing in U.S. companies from early to late stages with an emphasis on novel therapeutics and drug discovery. The firm typically leads investments and builds syndicates, applying hands-on involvement to optimize development programs and strategic positioning. venBio emphasizes strong intellectual property, robust chemistry, manufacturing and controls, and comprehensive clinical development plans, including trial design, endpoints, powering, and regulatory considerations, to help portfolio companies meet potential partner and acquisition criteria from the outset. It seeks to improve patient care through its portfolio and aims to form lasting relationships with leaders in the life sciences sector, with offices in San Francisco and Seattle and global operations.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including drug discovery and healthcare technology. It backs companies across the development spectrum, from early discovery to commercialization, with a long-term approach aimed at creating multiple product opportunities rather than quick exits. The firm manages substantial capital and operates an ecosystem of funds such as Platform, Opportunity, Labs-Soleil, and Crossover to support portfolio companies. Founded in 2007, The Column Group has generated significant returns for its partners and invested in numerous biotech ventures, including 55 companies with 18 exits. The organization emphasizes rigorous science, mentorship, and access to networks to advance portfolio programs in cancer, neurological, and other therapeutic areas.

Lumira Ventures is a North American venture capital firm focused on healthcare and life sciences companies, including biotechnology, biopharmaceuticals, medical devices, and digital health. It partners with entrepreneurs to develop and commercialize products addressing unmet medical needs. Headquartered in Toronto, Canada, the firm also has offices in Montreal, Vancouver, and Boston and invests primarily in Canada and the United States.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and first-round investments in technology and healthcare, with a broad remit across information technology, life sciences, media, energy, and emerging tech. The firm backs early- and growth-stage companies and has supported a number of notable portfolio companies, including Apple Computer, Intel, Illumina, Gilead Sciences, Endeca, Imperva, DoubleClick, Athenahealth, Centocor, Check Point Software, Nest, SlideShare, and Tudou. Venrock emphasizes partnering with entrepreneurs to build enduring companies and leverages its long history in technology and healthcare to help founders navigate growth, strategy, and complex markets.

Alumni Ventures is a venture capital firm that invests in startups from seed through late-stage, including pre-IPO companies, and provides strategic capital and support to founders. It gives accredited investors access to diversified venture portfolios and co-investment opportunities, including investments in companies connected to alumni communities. The firm is based in Manchester, New Hampshire, and operates across North America, with additional offices in London and Tokyo.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and life sciences companies. With leadership that has a long history of founding and supporting dozens of startups, the firm operates from Cambridge, Massachusetts and San Francisco, California, leveraging a network of researchers and venture capital partners. It provides mentorship, collaboration, and hands-on support from concept through clinical trials, including access to shared laboratory space through its Platinum Program, which offers up to $500,000 in funding, a lab bench, and related services for promising startups. The firm focuses on accelerating scientific solutions and actively participates in portfolio company growth across therapeutic areas, backing companies through multiple funds.

Pontifax is a healthcare-focused investment firm headquartered in Herzliya, Israel. It concentrates on life sciences and healthcare technologies, supporting companies across development stages with an emphasis on innovative biopharma, medical devices, biotechnology, and related sectors. The firm seeks to back transformative ideas through hands-on guidance and strategic support, aiming to help early-stage ventures grow and accelerate commercialization. While investing globally, Pontifax maintains a strong Israel focus and has built a portfolio spanning pharmaceuticals, diagnostics, and related fields, with a history dating to its founding in 2004.

MPM BioImpact is a biotechnology investment firm that builds and backs companies developing medicines for serious diseases. It invests across company stages, from early-stage startups to public companies, and provides scientific, clinical development, and company-building expertise. The firm is headquartered in Boston, Massachusetts, with an office in Brisbane, California, and invests in the United States, Europe, and Asia.

Vida Ventures is a biomedicine-focused venture capital and company-building firm that specializes in transforming biomedical innovations into therapies with the potential to improve patient lives. Founded in 2017 by scientists, physicians, entrepreneurs, and investors, Vida Ventures operates as a bi-coastal life sciences company building and investing in ventures. Vida Ventures backs companies across oncology, immunology, neurology, and genetic medicines, and has supported portfolio companies such as Aktis Oncology, Third Arc Bio, Scorpion Therapeutics, and InduPro. Vida Ventures emphasizes collaboration, innovation, and patient-centric approaches, and engages in company creation and value realization, including notable exits and financing rounds with major pharmaceutical outcomes. Vida Ventures seeks to advance science-to-therapy translation by combining scientific expertise with strategic industry connections to drive meaningful clinical and commercial impact.

Medicxi is a venture capital firm focused on the life sciences sector. Founded in 2016 by the former Index Ventures life sciences team, the firm is based in London, United Kingdom, with additional offices in Geneva and Jersey. Medicxi invests across seed, early, and later stages in Europe, targeting therapeutics, biotech, and technology-enabled healthcare companies. Building on decades of experience in drug discovery and development, the team supports ventures across a broad range of therapeutic areas, including vaccines, oncology, and neurology, helping firms advance research, development, and commercialization. The firm originated from Index Ventures and continues to back ambitious startups seeking to translate scientific advances into patient benefit, leveraging a hands-on approach and a network of biopharma partnerships.

Hatteras Venture Partners is a North Carolina based venture capital firm that invests in early-stage biotechnology, medical devices, diagnostics and other human medicine opportunities. Founded in 2000, the firm draws on more than two decades of healthcare experience to back high-quality science and capable teams, offering hands-on support such as recruitment and strategic planning in addition to capital. It maintains a health-centric investment approach and works with a broad network of industry partners to create optionality and accelerate value creation. While rooted in the Southeast, Hatteras operates nationally across bioscience ecosystems, seeking to help portfolio companies transition from ideas to scalable products that advance patient care and healthcare delivery.

Pivotal bioVenture Partners is a life sciences venture capital firm investing in healthcare companies developing therapies, diagnostics, medical devices, and related platforms. Its China team focuses on Greater China, while its U.S. team invests in therapeutic-focused companies across North America and Europe. The firm has offices in Shanghai, Hong Kong, and San Francisco.

Leaps by Bayer is the corporate venture arm of Bayer, investing in paradigm-shifting advances in life sciences. It focuses on biotechnology, agriculture, and other scientific breakthroughs to accelerate transformative technologies that could improve health care and agricultural sustainability. Established in 2015 and based in Leverkusen, Germany, Leaps pursues investments that aim to shift paradigms from symptom treatment to prevention or cure and to support innovations that address a growing population's needs while restoring the planet.

Khosla Ventures is a California-based venture capital firm founded in 2004 that backs technology-driven startups across multiple sectors, including artificial intelligence, healthcare, sustainability, digital health, and consumer technology. The firm provides capital and strategic guidance to companies at early and growth stages, with an emphasis on disruptive technologies and world-changing businesses. It operates a range of funds, including seed and later-stage vehicles, and maintains a broad investment thesis that covers AI, climate tech, energy efficiency, and other high-potential areas, primarily focused in the United States. The firm is known for working closely with entrepreneurs to build long-lasting companies.

Longitude Capital is a venture growth investment firm focused on life sciences, including biotechnology, medical technology, and health solutions. Established in 2006 and based in Menlo Park, California, it targets clinically de-risked assets across private and public life-science companies. The firm seeks to build balanced portfolios of clinical-stage and commercial-stage assets with attractive risk-adjusted returns within three to five years. It relies on a broad industry network and thematic research to identify opportunities in emerging therapeutic areas, and employs a range of investment structures such as traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open-market purchases, royalties, and other equity-linked instruments. The firm emphasizes strategic partnerships to support portfolio companies through fundraising and liquidity events.

Casdin Capital is a New York-based venture capital and investment firm focused on the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, the firm backs companies across genomic research, molecular medicine, precision medicine, diagnostics, synthetic biology, oncology, digital health, and related technologies. It pursues a data-driven, long-term investment approach and seeks to form strong partnerships with portfolio companies to advance scientific innovation and improve patient outcomes. The firm engages with ventures at various stages, from early- to late-stage private companies, emphasizing opportunities at the intersection of biology and technology. Through its activity in life sciences and healthcare, Casdin Capital positions itself as a partner to founders pursuing breakthroughs in genomics, molecular medicine, and AI-enabled healthcare platforms.

Ally Bridge Group is a global life sciences investment firm founded in 2013 and headquartered in New York, with a presence in Asia and Europe. It focuses on healthcare, biotechnology, medical technology, and related disruptive platforms, investing across private equity, venture, growth, and select public equities. The firm targets companies at early to development stages and aims to support transformative advances in drugs, diagnostics, medical devices, and related technologies. It emphasizes scientific and commercial conviction, proprietary research, and board-level engagement to help portfolio companies advance patient care, reduce costs, and expand global reach. Through its network, Ally Bridge Group collaborates with innovators to bridge research and commercialization, seeking meaningful impact beyond capital.

5AM Ventures is a venture capital firm founded in 2002 that invests in early-stage companies in biopharmaceuticals, life sciences, healthcare, medical technology, and research instruments. Headquartered in San Francisco, it also has an office in Boston and invests in companies across the United States.

Founded in 2007, Third Rock Ventures is a venture capital firm that invests in and helps build early-stage life sciences and healthcare companies, including businesses developing medicines, medical devices, diagnostics, and related technologies. It focuses on companies with potential to advance patient care and operates primarily in the United States. The firm is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Symbiosis Ventures is a venture capital firm focused on investing in early-stage biotechnology companies poised to transform healthcare through bioengineering. It targets ventures addressing life-threatening diseases with novel therapeutic platforms, preferably those with a lead candidate nearing human proof-of-concept and designed for manufacturability. The investment approach emphasizes objective, approvable endpoints and the use of advanced discovery tools. The firm has supported multiple biotech ventures, illustrating its focus on innovative therapeutic modalities and scalable development. It actively seeks new opportunities and evaluates non-confidential pitches from potential portfolio companies.

Aisling Capital is a New York-based venture capital and private equity firm founded in 2000 that specializes in healthcare and life sciences. The firm backs late-stage and growth companies developing innovative therapeutics, diagnostics, and medical technologies across the United States, Canada, and Western Europe, with a focus on advancing products to commercialization. Its portfolio has included companies across areas such as biotechnology, neuroscience, and regenerative medicine, and it seeks to support companies through capital and strategic guidance to translate scientific breakthroughs into patient care.

Catalio Capital Management is a New York-based investment firm focused on the full lifecycle of innovative healthcare companies across private, public, and credit markets. It pursues a multi-asset approach, including venture capital, structured opportunities, public equities, and co-investments, to back life sciences and technology-driven companies at various stages and capital structures. As of 2025, Catalio manages about $2 billion in assets and employs over 40 professionals across New York, Washington, DC, and London, supported by a network of roughly 45 venture partners who provide proprietary deal flow and domain expertise. The firm concentrates investments in drugs, AI-enabled technologies, and devices, and seeks strategic exits alongside ongoing value creation. Catalio emphasizes scientific leadership and collaboration with world-class scientists-entrepreneurs, aiming to translate breakthrough research into scalable healthcare solutions.

Longwood Fund is a venture capital firm based in Boston, Massachusetts, founded in 2010, focused on life sciences and healthcare. It invests in science-based companies that develop novel solutions for medical problems, primarily in biotechnology, pharmaceuticals, and related areas. The firm supports its portfolio from early-stage evaluation through clinical development and commercialization, leveraging a network of industry experts. Longwood highlights a track record of bringing therapies to patients, with more than 20 marketed products and roughly 25 therapies in late-stage development.

Lux Capital is a venture capital firm headquartered in New York City, with operations in Silicon Valley. It invests in companies applying scientific and technological advances across areas such as artificial intelligence, biotechnology, advanced materials, energy, aerospace, and infrastructure. The firm supports founders in building and growing businesses, from early-stage ventures to later-stage companies.

Merck is a research-driven biopharmaceutical company headquartered in Rahway, New Jersey. It discovers, develops, manufactures, and sells prescription medicines and vaccines for human health, including treatments for cancer, infectious diseases, and cardiometabolic conditions. The company also provides animal health products. Merck operates globally, serving patients and customers across regions worldwide.

Abingworth is an international life sciences investment firm founded in 1973 with offices in London, Boston, and Menlo Park. It collaborates with life sciences entrepreneurs to develop ideas into products that significantly impact health, investing across all development stages from startups to publicly traded companies and across all life sciences sectors. Supported by a team of 27 professionals, the firm has over $1 billion under management and has invested in 142 life science companies, with 60 IPOs and 40 mergers and acquisitions completed.

Sherpa Healthcare Partners is a China-based growth equity investment firm founded in 2018. It focuses on life sciences and healthcare, including pharmaceuticals, biotechnology, gene technology, medical devices, diagnostics, medical services, and oncology, and seeks to invest in and support sector leaders and innovators through strategic resources and collaborations to accelerate development and market adoption.